Traci McCarty | BioMarin Pharmaceutical, Inc. |
Jean-Jacques Bienaimé | BioMarin Pharmaceutical, Inc. |
Jeffrey Robert Ajer | BioMarin Pharmaceutical, Inc. |
Daniel K. Spiegelman | BioMarin Pharmaceutical, Inc. |
Henry J. Fuchs, M.D. | BioMarin Pharmaceutical, Inc. |
Robert A. Baffi | BioMarin Pharmaceutical, Inc. |
Cory W. Kasimov | JPMorgan Securities LLC |
Salveen Richter | Goldman Sachs & Co. LLC |
Joseph P. Schwartz | Leerink Partners LLC |
Robyn Karnauskas | Citigroup Global Markets, Inc. |
Christopher J. Raymond | Piper Jaffray & Co. |
Matthew K. Harrison | Morgan Stanley & Co. LLC |
Phil Nadeau | Cowen and Company, LLC |
Ying Huang | Bank of America Merrill Lynch |
Ashiq Mubarack | William Blair & Co. LLC |
Martin Auster | Credit Suisse Securities (NYSE:USA) LLC |
Timur Ivannikov | Raymond James & Associates, Inc. |
Kennen MacKay | RBC Capital Markets LLC |
Vincent Chen | Sanford C. Bernstein & Co. LLC |
Welcome to the BioMarin Second Quarter 2018 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Tracy.
Thank you, operator. Thank you, everyone, for joining us today.